LCAT and hyperlipidemia: SSTF was administrated at oral dosages of 25 mg, 50 mg, and 100 mg/kg/day in hyperlipidemia rats for 20 days, indicating that SSTF significantly reduced the serum TC, TG, and LDL-c levels and increased HDL-c and the activity of lecithin cholesterol acyltransferase (LCAT) [57].